Literature DB >> 8239623

In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

G J Malanoski1, L Collins, C Wennersten, R C Moellering, G M Eliopoulos.   

Abstract

The in vitro activity of biapenem, a new carbapenem previously designated L-627, was compared with those of imipenem and several other antimicrobial agents against 771 clinical bacterial isolates. Against gram-positive organisms, biapenem was found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates. Against gram-negative organisms and Bacteroides fragilis, biapenem was at least as active as and often more active than imipenem, with MICs for 90% of the isolates two- to eightfold lower than those of imipenem.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239623      PMCID: PMC188112          DOI: 10.1128/AAC.37.9.2009

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.

Authors:  P J Petersen; N V Jacobus; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

Authors:  G M Eliopoulos; K Klimm; M J Ferraro; G A Jacoby; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

5.  In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.

Authors:  S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  Purification and characterization of inducible beta-lactamases in Aeromonas spp.

Authors:  J P Iaconis; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  In vitro activity of L-627, a new carbapenem.

Authors:  C R Catchpole; R Wise; D Thornber; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  7 in total
  9 in total

1.  In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.

Authors:  A E Simor; L Louie; M Louie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.

Authors:  K E Aldridge; N Morice; D D Schiro
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.

Authors:  Ellie J C Goldstein; Diane M Citron; Kerin L Tyrrell; C Vreni Merriam
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

7.  Interactions of biapenem with active-site serine and metallo-beta-lactamases.

Authors:  A Felici; M Perilli; B Segatore; N Franceschini; D Setacci; A Oratore; S Stefani; M Galleni; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Comparative in vitro activities of L-695,256, a novel carbapenem, against gram-positive bacteria.

Authors:  G Malanoski; L Collins; C T Eliopoulos; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

9.  Structure of apo- and monometalated forms of NDM-1--a highly potent carbapenem-hydrolyzing metallo-β-lactamase.

Authors:  Youngchang Kim; Christine Tesar; Joseph Mire; Robert Jedrzejczak; Andrew Binkowski; Gyorgy Babnigg; James Sacchettini; Andrzej Joachimiak
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.